PLANTATION, Fla., Nov. 15, 2021 /CNW/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU) ("Akumin" or the "Corporation") announced today its financial results for the quarter ended June 30, 2021 ("Q2 Fiscal 2021"), as well as the filing of its restated annual financial statements for the periods ended December 31, 2020 and 2019 and its restated interim financial statements for the quarter ended March 31, 2021 (the "Restated Financial Statements").

Q2 Fiscal 2021

Summary Consolidated Financial Results (in thousands, except for per share amounts)



(Restated)


(Restated)


3-month period
ended

Jun. 30, 2021

3-month period
ended

Jun. 30, 2020

6-month period
ended

Jun. 30, 2021

6-month period
ended

Jun. 30, 2020

Volume in RVUs

1,659

1,094

3,174

2,619

Revenue

69,496

47,365

133,459

115,535

EBITDA (1)

6,153

4,428

16,201

14,252

Adjusted EBITDA (1)

11,685

5,636

20,583

15,545

EPS –Diluted

(0.10)

(0.11)

(0.15)

(0.15)

(1) See "Non-GAAP Measures" below.

Commenting on the Q2 Fiscal 2021 financial results, Riadh Zine, Chairman and Co-Chief Executive Officer of the Corporation, said, "During the quarter, we generated revenue of $69.5 million, which is in-line with consensus estimates.  After taking into account the revised approach to implicit price concessions reflected in our restated financial statements, the total service fee revenue per RVU during the second quarter of 2021 was $41, as compared to $42 after the restatement for the full fiscal 2020.  Prior to the restatement, we showed total service fee revenue per RVU of $43 for fiscal 2020.

"Akumin's volume for the quarter was approximately 1,659,000 RVUs, compared to approximately 1,094,000 RVUs in the same quarter last year.  This represents an increase of 52% year-over-year and a 10% increase compared to Q1 2021.  On an organic volume basis, RVUs increased by 45% compared to the same prior period, which was significantly impacted by the COVID-19 pandemic.  Volumes for the quarter are in-line with pre-pandemic levels in most regions where we currently operate.

"Adjusted EBITDA during the quarter was $11.7 million as compared to $5.6 million in the same period last year," Mr. Zine concluded.

Restated Financial Statements and Delayed Q3 Filings

As previously announced, Akumin has restated its annual financial statements for the years ended December 31, 2020 and 2019 and its interim financial statements for the period ended March 31, 2021, as well as the management's discussion and analysis for those periods.

The Restated Financial Statements were necessary because management determined corrections were required relating to its estimates for implicit price concessions on historic accounts receivable and because certain costs relating to the replacement of certain component parts that were previously capitalized should more accurately be expensed as repair and maintenance. In accordance with the prior disclosure in Akumin's press releases dated October 12, 2021 and November 8, 2021, the changes made in the Restated Financial Statements resulted in an accounts receivable balance as at June 30, 2021 shown in the Q2 Fiscal 2021 financial statements of $67.6 million, and a restated balance as at March 31, 2021 of $64.2 million, as compared to Akumin's previously reported March 31, 2021 accounts receivable balance of $95.9 million, and a net book value of property and equipment as at June 30, 2021 shown in the Q2 Fiscal 2021 financial statements of $60.4 million, and a restated net book value as at March 31, 2021 of $61.6 million, as compared to Akumin's previously reported March 31, 2021 net book value of property and equipment of $79.2 million.

As disclosed previously, given preparation of the Restated Financial Statements and Akumin's interim financial statements for Q2 Fiscal 2021 has impacted the timely completion, and auditor's review, of Akumin's interim financial statements for the quarter ended September 30, 2021, Akumin will not be able file its interim financial results for the quarter ended September 30, 2021, and the related management's discussion and analysis and CEO and CFO certificates (collectively, the "Q3 Filings") by today's reporting deadline of November 15, 2021. Akumin is currently working to complete the Q3 Filings and the auditor's review of such filings at the earliest possible date and currently expects to be in a position to file the Q3 Filings by December 15, 2021.

In light of the delays related to Akumin's Q3 Filings, Akumin anticipates that it will continue to be subject to the management cease trade order granted by the Ontario Securities Commission (the "OSC"), as principal regulator of Akumin, on August 20, 2021 (the "MCTO") under National Policy 12-203 – Management Cease Trader Orders ("NP 12-203") until such order is rescinded by the OSC following Akumin's filing of the Q3 Filings. Akumin confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements and the MCTO continues to apply.

"We appreciate the patience of our various stakeholders as we've worked to address the issues identified in our review of Akumin's Q2 and historic financial results," said Mr. Zine with respect to the filings. "We believe the robust review process undertaken is reflective of our prudent approach to ensuring the integrity of our financial statements and public filings. We continue to work hard to complete our Q3 filings as expeditiously as possible and look forward to returning to business as usual going forward, with a focus on maximizing the value of our combined company as we continue to integrate the Alliance acquisition."

Akumin Completed Acquisition of Alliance

As previously announced, subsequent to the end of the quarter, Akumin closed its acquisition of Alliance HealthCare Services, Inc. on September 1, 2021 for a purchase price of $820 million.

"Akumin is now a powerhouse in outpatient healthcare solutions well positioned to play a significant role in a changing healthcare ecosystem that is shifting rapidly toward an outpatient setting," Mr. Zine said with respect to the acquisition.  "The Corporation offers multiple healthcare services, has long-standing relationships with hospitals, health systems and physician groups, and possesses the scale and experience to drive efficiencies, innovation, and organic growth."

"As the partner of choice to hospital, health systems and physicians in outpatient imaging and cancer care services, our team will continue to put patient experience at the heart of what we do, while fully integrating the corporate and shared services of the organization to support all our healthcare solutions in all the communities that we serve," added Rhonda Longmore-Grund, President and Co-Chief Executive Officer.

Foreign Private Issuer Status

As contemplated by the Corporation's management information circular dated April 7, 2021, the Corporation determined that as of June 30, 2021, more than 50% of its outstanding voting securities are held by U.S. residents.  Because more than 50% of the Corporation's assets are located in, and Akumin's business is administered principally in, the United States, as of January 1, 2022, Akumin will no longer qualify as a foreign private issuer.  As a result, from and after January 1, 2022, in addition to other obligations, Akumin will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the Securities and Exchange Commission.  These filings are more detailed and extensive in certain respects, and must be filed more promptly, than the forms available to Akumin as a foreign private issuer.

About Akumin

Akumin is a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service line needs. With the acquisition of Alliance HealthCare Services, Akumin now provides (1) freestanding, fixed-site outpatient diagnostic imaging services through a network of more than 170 owned and/or operated independent imaging centers located in 11 states; and (2) outpatient radiology and oncology solutions to more than 1,000 hospitals and health systems in 46 states. By combining clinical and operational expertise with the latest advances in technology and information systems, Akumin and its ~4,000 Team Members facilitate more efficient and effective diagnosis and treatment for patients and their providers in 46 states. Akumin's imaging procedures include MRI, CT, positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and other interventional procedures; our cancer care services include a full suite of radiation therapy and related offerings. For more information, visit www.akumin.com and www.alliancehealthcareservices-us.com.

Non-GAAP Measures

This press release refers to certain non-GAAP measures. These non-GAAP measures are not recognized measures under United States generally accepted accounting principles ("GAAP") and do not have a standardized meaning prescribed by GAAP.  There is unlikely to be comparable or similar measures presented by other companies. Rather, these non-GAAP measures are provided as additional information to complement those GAAP measures by providing further understanding of our results of operations from management's perspective. Accordingly, these non-GAAP measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under GAAP. We use non-GAAP financial measures, including "EBITDA", "Adjusted EBITDA", "Adjusted EBITDA Margin" and "Adjusted net income (loss) attributable to shareholders of Akumin" (each as defined below). These non-GAAP measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on GAAP measures. We believe the use of these non-GAAP measures, along with GAAP financial measures, enhances the reader's understanding of our operating results and is useful to us and to investors in comparing performance with competitors, estimating enterprise value, and making investment decisions.  We also believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management uses non-GAAP measures to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Definitions and reconciliations of non-GAAP measures to the relevant reported measures can be found in our Management's Discussion and Analysis dated August 16, 2021 available in our public disclosure at www.sedar.com and www.sec.gov.

We define such non-GAAP measures as follows:

"EBITDA" means net income (loss) attributable to shareholders of the Corporation before interest expense (net), income tax expense (benefit) and depreciation and amortization.

"Adjusted EBITDA" means EBITDA, as further adjusted for stock-based compensation, impairment of property and equipment, provisions for certain credit losses, settlement costs, provisions, acquisition-related and public offering costs, gains (losses) in the period, deferred rent expense (credit) and one-time adjustments.

"Adjusted EBITDA Margin" means Adjusted EBITDA divided by the total revenue in the period.

"Adjusted net income (loss) attributable to shareholders of Akumin" means Adjusted EBITDA less depreciation and amortization and interest expense, taxed at Akumin's estimated effective tax rate, which is a blend of U.S. federal and state statutory tax rates for Akumin for the period.

Forward-Looking Information

Certain information in this press release constitutes forward-looking information.  In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.  Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. In particular, this release contains forward-looking information relating to the anticipated filing of the Q3 Filings, the continued application of the MCTO, Akumin's intentions to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and Akumin's ceasing to qualify as a foreign private issuer.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of our management's discussion and analysis for the quarter ended June 30, 2021 dated November 15, 2021, which is available at www.sedar.com and www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully.  There can be no assurance that such estimates and assumptions will prove to be correct.  The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Selected Consolidated Financial Information



(Restated)

(in thousands)

Three-month period
ended
Jun 30, 2021

Three-month period
ended
Jun 30, 2020

Service fees – net of allowances and discounts

68,243

45,821

Other revenue

1,253

1,544

Revenue

69,496

47,365




Employee compensation

23,792

15,881

Reading fees

10,860

7,423

Rent and utilities

7,662

8,309

Third party services and professional fees

8,492

6,818

Administrative

4,095

2,494

Medical supplies and other expenses

2,867

2,282

Depreciation and amortization

4,584

4,368

Stock-based compensation

785

566

Operational financial instruments revaluation and other (gains) losses

256

(1,785)

Interest expense

8,920

8,014

Settlement costs (recoveries)

(318)

524

Acquisition related costs

4,350

81

Other financial instruments revaluation and other (gains) losses

-

(96)

Income (loss) before income taxes

(6,849)

(7,514)

Income tax provision (benefit)

6

(17)

Non-controlling interests

502

440

Net income (loss) attributable to shareholders of Akumin

(7,357)

(7,937)

 



(Restated)

Adjusted EBITDA

(in thousands)

Three-month period
ended
Jun 30, 2021

Three-month period
ended
Jun 30, 2020

Revenue

69,496

47,365

Less:



Employee compensation

23,792

15,881

Reading fees

10,860

7,423

Rent and utilities

7,662

8,309

Third party services and professional fees

8,492

6,818

Administrative

4,095

2,494

Medical supplies and other expenses

2,867

2,282

Deferred rent (expense) credit

(459)

(1,918)

Sub-total

57,309

41,289

Non-controlling interests

502

440

Adjusted EBITDA

11,685

5,636

Adjusted EBITDA Margin

17%

12%

 



(Restated)

(in thousands)

Six-month period
ended
Jun 30, 2021

Six-month period
ended
Jun 30, 2020

Service fees – net of allowances and discounts

131,709

113,366

Other revenue

1,750

2,169

Revenue

133,459

115,535




Employee compensation

46,909

40,699

Reading fees

20,844

18,346

Rent and utilities

15,346

15,818

Third party services and professional fees

16,140

15,221

Administrative

7,662

6,249

Medical supplies and other expenses

6,008

5,209

Depreciation and amortization

9,073

8,643

Stock-based compensation

1,212

1,158

Operational financial instruments revaluation and other (gains) losses

346

(8,113)

Interest expense

17,288

15,477

Settlement costs (recoveries)

(342)

880

Acquisition related costs

5,628

300

Other financial instruments revaluation and other (gains) losses

(3,366)

4,475

Income (loss) before income taxes

(9,289)

(8,827)

Income tax provision (benefit)

71

972

Non-controlling interests

871

1,041

Net income (loss) attributable to shareholders of Akumin

(10,231)

(10,840)

 



(Restated)

Adjusted EBITDA

(in thousands)

Six-month period
ended
Jun 30, 2021

Six-month period
ended
Jun 30, 2020

Revenue

133,459

115,535

Less:



Employee compensation

46,909

40,699

Reading fees

20,844

18,346

Rent and utilities

15,346

15,818

Third party services and professional fees

16,140

15,221

Administrative

7,662

6,249

Medical supplies and other expenses

6,008

5,209

Deferred rent (expense) credit

(904)

(2,593)

Sub-total

112,005

98,949

Non-controlling interests

871

1,041

Adjusted EBITDA

20,583

15,545

Adjusted EBITDA Margin

15%

13%

 

Reconciliation of Non-GAAP Measures



(Restated)


(Restated)

(in thousands)

Three-month
period

ended
Jun 30, 2021

Three-month
period

ended
Jun 30, 2020

Six-month
period

ended
Jun 30, 2021

Six-month
period

ended
Jun 30, 2020

Net income (loss) attributable
to shareholders of Akumin

(7,357)

(7,937)

(10,231)

(10,840)

Income tax provision (benefit)

6

(17)

71

972

Depreciation and amortization

4,584

4,368

9,073

8,643

Interest expense

8,920

8,014

17,288

15,477

EBITDA

6,153

4,428

16,201

14,252

Adjustments:





Stock-based compensation

785

566

1,212

1,158

Settlement costs (recoveries)

(318)

524

(342)

880

Acquisition-related costs

4,350

81

5,628

300

Operational financial instrument
revaluation and other (gains)
losses

256

(1,785)

346

(8,113)

Other financial instruments
revaluation and other (gains)
losses

-

(96)

(3,366)

4,475

Deferred rent expense (credit)(1)

459

1,918

904

2,593

Adjusted EBITDA

11,685

5,636

20,583

15,545

Revenue

69,496

47,365

133,459

115,535

Adjusted EBITDA Margin

17%

12%

15%

13%






Adjusted EBITDA

11,685

5,636

20,583

15,545

Less:





Depreciation and amortization

4,584

4,368

9,073

8,643

Interest expense

8,920

8,014

17,288

15,477

Sub-total

(1,819)

(6,746)

(5,778)

(8,575)

Effective tax rate(2)

23.9%

24.1%

23.9%

24.1%

Tax effect

(434)

(1,626)

(1,378)

(2,067)

Adjusted net income (loss)
attributable to shareholders of
Akumin

(1,385)

(5,120)

(4,400)

(6,508)

(1)

Based on note 9 of the Corporation's Q2 2021 Financial Statements; Deferred rent expense (credit) is defined as operating lease cost less operating cash flows from operating leases.

(2)

Akumin's estimated effective tax rate is a blend of U.S. federal and state statutory tax rates for the period.

 

SOURCE Akumin Inc.

Copyright 2021 Canada NewsWire

Akumin (TSX:AKU)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Akumin Charts.
Akumin (TSX:AKU)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Akumin Charts.